Trial Profile
A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2019
Price :
$35
*
At a glance
- Drugs Ensifentrine (Primary) ; Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Verona Pharma
- 30 Aug 2018 Results of pooled data from two trials (NCT02542254 and NCT03028142), were published in the European Respiratory Journal.
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society.
- 21 May 2018 Results presented in a Verona Pharma media release.